Aprea Therapeutics (APRE) - צמיחת רווחי EPS רבעונית
Aprea Therapeutics (APRE) is accelerating drug synthesis through robotic analysis systems. The GURU.Markets service features a line chart where the quarterly earnings per share trend shows that the metric value is 80.20. Aprea Therapeutics is developing DNA damage inhibitors through clinical alliances and M&A, focusing on early-stage development of targeted drugs to attract major pharmaceutical partners.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9E%D7%A9%D7%A0%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%91-12%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_APRE_-_Aprea-Therapeutics_-_Year-over-year-net-earnings-per-share-growth-for-the-last-12-months "צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים Aprea (APRE): לתקופה 04.07.2022 - 14.11.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת Aprea Therapeutics
The efficiency of transporting Aprea Therapeutics (APRE) targeted drugs under climate control directly impacts operating expenses, determining the final net profit. This metric measures the percentage change in earnings per share relative to the previous quarter, reflecting the business's profitability dynamics, which allows investors to assess the company's cost resilience and the risk of future drawdowns through quarterly EPS fluctuations.
